Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Immune ThrombocytopeniaTreatment
Interventions
DRUG

Avatrombopag

"After enrollment, all subjects receive Avatrombopag treatment. The initial dose of Avatrombopag administration was an oral 10 mg (\<30kg) or 20mg (≥30kg) once daily in all participants. ps. For subjects weighing ≥30kg, the dose can be started from 40mg once daily if the platelet count is \< 10×10\^9/L or if there is severe bleeding or risk of bleeding.~Complete blood count including platelet count was done once a week. The dose of Avatrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count was less than 30×10\^9/L for 2 weeks, avatrobopag was gradually increased. If the platelet count was greater than 150 x 10\^9/L, avatrobopag was gradually reduced. If the platelet count \>250×10\^9/L, avatrobopag will be stoped until the platelet count \<100×10\^9/L."

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin

All Listed Sponsors
collaborator

Henan Cancer Hospital

OTHER_GOV

collaborator

Tianjin Medical University Second Hospital

OTHER

collaborator

Tianjin Children's Hospital

OTHER

collaborator

The Second Affiliated Hospital of Kunming Medical University

OTHER

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER